Bluejay Diagnostics, Inc. Selling, General and Administrative Expense
Bluejay Diagnostics, Inc. (BJDX) reported Selling, General and Administrative Expense of $6.42 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-05-15
- Bluejay Diagnostics, Inc. selling, general and administrative expense for the quarter ending 2024-03-31 was $6.42K, a 95.66% decline year-over-year.
- Bluejay Diagnostics, Inc. selling, general and administrative expense for the quarter ending 2023-12-31 was $687.00, a 99.60% decline year-over-year.
- Bluejay Diagnostics, Inc. selling, general and administrative expense for the quarter ending 2023-09-30 was -$19.62K, a 113.43% decline year-over-year.
- Bluejay Diagnostics, Inc. selling, general and administrative expense for the quarter ending 2023-03-31 was $148.05K.
- Bluejay Diagnostics, Inc. selling, general and administrative expense for fiscal 2023 was $283.44K, a 37.21% decline from fiscal 2022.
- Bluejay Diagnostics, Inc. selling, general and administrative expense for fiscal 2022 was $451.42K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $6.42K 10-Q · filed 2024-05-15 | $7.11K derived: sum of 2 quarters · filed 2024-05-15 | -$12.51K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2023-12-31 | $687.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$18.93K derived: sum of 2 quarters · filed 2024-03-28 | $283.44K 10-K · filed 2024-03-28 | |
| 2023-09-30 | -$19.62K 10-Q · filed 2023-11-09 | $282.76K 10-Q · filed 2023-11-09 | ||
| 2023-03-31 | $148.05K 10-Q · filed 2024-05-15 | $318.32K derived: sum of 2 quarters · filed 2024-05-15 | $464.43K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $170.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $316.38K derived: sum of 2 quarters · filed 2024-03-28 | $451.42K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $146.10K 10-Q · filed 2023-11-09 | $281.14K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |